Cumulative incidence of clinically relevant hyperuricaemic events* for patients treated with empagliflozin vs. placebo.*Clinically relevant hyperuricemia is defined as the composite episodes of acute gout, gouty arthritis or the initiation of treatment with serum uric acid lowering therapy (xanthine oxidase inhibitors, uricosuric agents or colchicine).